Medication info

Pregabalin 75 mg Capsules

Prescription medicationHard capsuleOralApproval withdrawn
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Highple Life Science Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow in color.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Approval withdrawn

MFDS item code 201905824 · Approved 2019.08.19

This product's status changed to Approval withdrawn on 2024.03.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medication is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once as an additional dose. 6. Patients with Hepatic Impairment No dose adjustment is required in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because sufficient safety and efficacy data are not available. Adolescent patients aged 12 ~17 years: Administration is not recommended because sufficient safety and efficacy data are not available.

Ingredients

Manufacturer
Highple Life Science Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults and is also used as an adjunct in the treatment of partial seizures in patients with epilepsy. It is effective in alleviating the symptoms of fibromyalgia, and as such, is widely used in the treatment of neuralgia and related disorders.

How to take

Adult dose

This medication is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once as an additional dose. 6. Patients with Hepatic Impairment No dose adjustment is required in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because sufficient safety and efficacy data are not available. Adolescent patients aged 12 ~17 years: Administration is not recommended because sufficient safety and efficacy data are not available.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so if symptoms of depression, mood changes, or unusual behavior occur during treatment, healthcare providers should be notified immediately. This medication should not be taken by individuals with allergies to any of its ingredients or specific genetic metabolic problems. Diabetic patients should be cautious as weight gain may require adjustments in the dosage of blood glucose-lowering medications. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, use should be stopped immediately. Elderly individuals may experience dizziness, drowsiness, or mental confusion and should be particularly cautious until they become accustomed to the medication. Blurred vision or changes in vision may occur; if these symptoms appear, consult a physician. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, and dosage should be gradually reduced under medical supervision. Due to the risk of drug abuse or dependence, patients with a history of substance abuse should use this medication with caution. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should use this medication carefully, taking into account potential risks of congestive heart failure. Caution is advised when taking this medication alongside other central nervous system depressants due to an increased risk of respiratory depression. Pregnant women or those planning to become pregnant should consult their physician before taking this medication due to risks of fetal malformation, and effective contraceptive methods should be used. Nursing mothers should carefully consider the decision to breastfeed as this medication can transfer into breast milk and may affect the baby. There is a risk of accidents due to dizziness and drowsiness during driving or operating machinery after taking this medication; such activities should be avoided if these symptoms appear. In case of overdose, symptoms like confusion, drowsiness, depression, and seizures may occur, and emergency treatment should be sought immediately. When taken by children or the elderly, this medication should be stored out of the reach of children, and it is advisable not to transfer the capsules to other containers. Although rare, this medication may cause serious side effects such as skin rash, severe allergic reactions, and difficulty breathing; if any unusual symptoms occur, discontinuation and medical consultation are advised.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 184 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • depression
  • pain
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • flatulence
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decrease
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • hives
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory disturbances
  • fatigue
  • tightness in the chest
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • poor appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hyperesthesia
  • anxiety
  • mood swings
  • emotional lability
  • emotional elevation
  • difficulty in finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • motor coordination disturbances
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory decrease
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • tonic spasms
  • decreased reflexes
  • movement abnormalities
  • psychomotor agitation
  • orthostatic dizziness
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • diplopia
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • respiratory distress
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngitis
  • nasal dryness
  • respiratory depression
  • headache
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • fatigue
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusion state
  • agitation
  • restlessness
  • seizures
  • worsening of convulsions
  • sleep disorders
  • skin diseases
  • bloody stool
  • tinnitus
  • constipation
  • gastrointestinal disorders
  • weakness
  • and obstruction syndrome
  • intestinal obstruction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container, protected from air and light, and kept at room temperature between 15 to 30 degrees Celsius. This storage method helps maintain the medication's effectiveness and prevents degradation.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow in color.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.